Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kalos

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Cancer Immunology Research|September 26, 2014
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanomaDavid L Bajor, Xiaowei Xu, Drew A Torigian, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
The Journal of Experimental Medicine|June 5, 2002
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector functionClaes Ohlén, Michael Kalos, Laurence E Cheng, et al.
Blood|April 12, 2015
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patientsMichael A Pulsipher, Chris Carlson, Bryan Langholz, et al.
Cancer Immunology Research|March 1, 2014
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignanciesGregory L Beatty, Andrew R Haas, Marcela V Maus, et al.
The American Journal of Pathology|January 10, 2014
The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytesQian Zhang, Fang Wei, Hong Yi Wang, et al.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Blood|May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyDavid T Teachey, Susan R Rheingold, Shannon L Maude, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Cancer Immunology Research|September 26, 2014
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanomaDavid L Bajor, Xiaowei Xu, Drew A Torigian, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
The Journal of Experimental Medicine|June 5, 2002
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector functionClaes Ohlén, Michael Kalos, Laurence E Cheng, et al.
Blood|April 12, 2015
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patientsMichael A Pulsipher, Chris Carlson, Bryan Langholz, et al.
Cancer Immunology Research|March 1, 2014
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignanciesGregory L Beatty, Andrew R Haas, Marcela V Maus, et al.
The American Journal of Pathology|January 10, 2014
The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytesQian Zhang, Fang Wei, Hong Yi Wang, et al.
Plos One|July 18, 2022
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor modelsYanxia Li, Nelusha Amaladas, Marguerita O'Mahony, et al.
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Cytotherapy|March 23, 2020
Accelerating the development of innovative cellular therapy products for the treatment of cancerMark D Stewart, Anne Keane, Lisa H Butterfield, et al.
Blood|May 17, 2013
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyDavid T Teachey, Susan R Rheingold, Shannon L Maude, et al.
Pageof 8